Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
2.
Circ Cardiovasc Interv ; 15(11): 861-871, 2022 11.
Article in English | MEDLINE | ID: mdl-36111801

ABSTRACT

BACKGROUND: There is little information available on agreement between fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) in left main coronary artery (LMCA) intermediate stenosis. Besides, several meta-analyses support the use of FFR to guide LMCA revascularization, but limited information is available on iFR in this setting. Our aims were to establish the concordance between FFR and iFR in intermediate LMCA lesions, to evaluate with intravascular ultrasound (IVUS) in cases of FFR/iFR discordance, and to prospectively validate the safety of deferring revascularization based on a hybrid decision-making strategy combining iFR and IVUS. METHODS: Prospective, observational, multicenter registry with 300 consecutive patients with intermediate LMCA stenosis who underwent FFR and iFR and, in case of discordance, IVUS and minimal lumen area measurements. Primary clinical end point was a composite of cardiovascular death, LMCA lesion-related nonfatal myocardial infarction, or unplanned LMCA revascularization. RESULTS: FFR and iFR had an agreement of 80% (both positive in 67 and both negative in 167 patients); in case of disagreement (31 FFR+/iFR- and 29 FFR-/iFR+) minimal lumen area was ≥6 mm2 in 8.7% of patients with FFR+ and 14.6% with iFR+. Among the 300 patients, 105 (35%) underwent revascularization and 181 (60%) were deferred according to iFR and IVUS. At a median follow-up of 20 months, major adverse cardiac events incidence was 8.3% in the defer group and 13.3% in the revascularization group (hazard ratio, 0.71 [95% CI 0.30-1.72]; P=0.45). CONCLUSIONS: In patients with intermediate LMCA stenosis, a physiology-guided treatment decision is feasible either with FFR or iFR with moderate concordance between both indices. In case of disagreement, the use of IVUS may be useful to indicate revascularization. Deferral of revascularization based on iFR appears to be safe in terms of major adverse cardiac events. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT03767621.


Subject(s)
Coronary Stenosis , Fractional Flow Reserve, Myocardial , Humans , Prognosis , Coronary Angiography , Prospective Studies , Constriction, Pathologic , Treatment Outcome , Coronary Stenosis/diagnostic imaging , Coronary Stenosis/therapy , Coronary Vessels/diagnostic imaging , Severity of Illness Index , Ultrasonography, Interventional , Predictive Value of Tests , Cardiac Catheterization
3.
Cardiology ; 146(4): 426-430, 2021.
Article in English | MEDLINE | ID: mdl-33756460

ABSTRACT

BACKGROUND: Acetylsalicylic acid hypersensitivity (ASAH) limits therapeutic options in patients with acute coronary syndrome (ACS), who benefit from dual antiplatelet therapy (DAPT), especially when undergoing stent implantation. Our aim was to evaluate the safety and efficacy of triflusal in patients with ACS and ASAH. METHODS AND RESULTS: Two-center retrospective study of patients diagnosed with ACS and ASAH from January 1, 2000, to May 1, 2020. Sixty-six patients were treated with triflusal. ASAH was confirmed with tests in 15 patients (22.7%). Forty-nine patients (74.2%) presented history of other drug allergies. Fifty-nine patients (89.4%) underwent stent implantation. DAPT was prescribed for ≥12 months in 54 patients. No adverse reactions to triflusal were reported. During a median follow-up of 5.12 years [IQR 2.7-9.9], rate of cardiovascular (CV) mortality was 6.1%, nonfatal myocardial infarction 12.1%, and ischemic stroke 4.5%. No cases of definite stent thrombosis occurred. Bleeding Academic Research Consortium grade ≥2 was observed in 3 patients during follow-up. CONCLUSION: In this series of patients presenting with ACS and ASA hypersensitivity, triflusal showed good tolerability and was associated with a low rate of CV and bleeding events.


Subject(s)
Acute Coronary Syndrome , Percutaneous Coronary Intervention , Acute Coronary Syndrome/drug therapy , Aspirin/adverse effects , Drug Therapy, Combination , Humans , Platelet Aggregation Inhibitors/adverse effects , Retrospective Studies , Salicylates , Treatment Outcome
7.
Emerg Infect Dis ; 23(12): 2091-2093, 2017 12.
Article in English | MEDLINE | ID: mdl-29148392

ABSTRACT

We report an unusual case of myopericarditis caused by Rickettsia sibirica mongolitimonae. Because of increasing reports of Rickettsia spp. as etiologic agents of acute myopericarditis and the ease and success with which it was treated in the patient reported here, rickettsial infection should be included in the differential diagnosis for myopericarditis.


Subject(s)
DNA, Bacterial/genetics , Myocarditis/diagnosis , Pericarditis/diagnosis , Rickettsia Infections/diagnosis , Rickettsia/pathogenicity , Acute Disease , Adult , Animals , Anti-Bacterial Agents/therapeutic use , Diagnosis, Differential , Doxycycline/therapeutic use , Humans , Male , Myocarditis/drug therapy , Myocarditis/microbiology , Myocarditis/physiopathology , Pericarditis/drug therapy , Pericarditis/microbiology , Pericarditis/physiopathology , Rickettsia/genetics , Rickettsia/isolation & purification , Rickettsia Infections/drug therapy , Rickettsia Infections/microbiology , Rickettsia Infections/physiopathology , Treatment Outcome
10.
J Invasive Cardiol ; 24(6): E119-21, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22684392

ABSTRACT

Factor VII deficiency (FVIId) is a congenital coagulation disorder with a wide spectrum of bleeding phenotypes. Percutaneous coronary intervention requires full anticoagulation during stent implantation to avoid acute coronary thrombosis and long-term dual antiplatelet therapy. Feasibility of percutaneous coronary intervention in FVIId is not described in literature. We present a successful case of percutaneous coronary intervention in a 55-year-old male with FVIId, discussing briefly the periprocedural handicaps (anticoagulation regimen and hemostasis at arterial puncture site) as the safety of long-term antiplatelet therapy, and future implications for recombinant FVIId administration in a patient with a previous coronary stent.


Subject(s)
Angioplasty, Balloon, Coronary/methods , Coronary Stenosis/therapy , Factor VII Deficiency/diagnosis , Platelet Aggregation Inhibitors/administration & dosage , Stents , Angina Pectoris/complications , Angina Pectoris/diagnostic imaging , Aspirin/administration & dosage , Clopidogrel , Coronary Stenosis/complications , Coronary Stenosis/diagnostic imaging , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/diagnosis , Factor VII Deficiency/complications , Factor VII Deficiency/drug therapy , Follow-Up Studies , Humans , Male , Middle Aged , Obesity, Morbid/complications , Obesity, Morbid/diagnosis , Radiography , Risk Assessment , Thromboembolism/prevention & control , Ticlopidine/administration & dosage , Ticlopidine/analogs & derivatives , Time Factors , Treatment Outcome
12.
Cardiol J ; 16(1): 68-72, 2009.
Article in English | MEDLINE | ID: mdl-19130418

ABSTRACT

BACKGROUND: Valve replacement for aortic stenosis (AS) determines negative ventricular remodelling. We used cross sectional and Doppler echocardiography to check how rapidly it occurs and to assess if these changes are sustained over time. METHODS: We evaluated in 34 patients subjected to aortic valve replacement for AS morphological and functional (ejection fraction and E:A ratio) left ventricular data by echocardiography prior to surgery and 2 postoperative studies: early after surgery (pQ1) and at mid-term evolution (pQ2). RESULTS: Left ventricular mass index was reduced at pQ1 (from 152 +/- 47 g/m2 to 113 +/- 31 g/m2; p < 0.01) as well as end-diastolic (from 51.3 mm to 48.3 mm; p < 0.03), end-systolic (from 32.2 mm to 29.4 mm; p < 0.02), interventricular septum (from 12.9 mm to 10.3 mm; p < 0.01), and posterior wall (from 12.5 mm to 11 mm; p < 0.01) dimensions. Left ventricular ejection fraction (from 61.2% to 65.2%; p < 0.04) and E:A ratio (from 0.94 to 0.98; p < 0.01) increased significantly at pQ1. There were no significant differences in measurements between pQ1 and pQ2. CONCLUSIONS: Aortic valve replacement surgery leads to a rapid negative left ventricular remodelling during the first 7 months, including a decrease in myocardial hypertrophy and an improvement in systolic and diastolic function. These beneficial hemodynamic changes are sustained for at least 3 years.


Subject(s)
Aortic Valve Stenosis/surgery , Heart Valve Prosthesis Implantation , Heart Ventricles/physiopathology , Hypertrophy, Left Ventricular/etiology , Ventricular Remodeling , Aged , Aortic Valve Stenosis/complications , Aortic Valve Stenosis/diagnostic imaging , Aortic Valve Stenosis/physiopathology , Echocardiography, Doppler , Female , Heart Ventricles/diagnostic imaging , Humans , Hypertrophy, Left Ventricular/diagnostic imaging , Hypertrophy, Left Ventricular/physiopathology , Hypertrophy, Left Ventricular/surgery , Male , Middle Aged , Retrospective Studies , Stroke Volume , Time Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...